Lifesci Capital assumed coverage on shares of Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) in a research report issued to clients and investors on Wednesday, Marketbeat reports. The ...

Fintel reports that on March 12, 2025, LifeSci Capital initiated coverage of Monte Rosa Therapeutics (NasdaqGS:GLUE) with a ...

LifeSci Capital initiated coverage of Monte Rosa Therapeutics (GLUE) with an Outperform rating and $19 price target Optimize Your Investment ...

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to ...

Monte Rosa Therapeutics bounded higher on Monday, as shares nearly doubled on a deal with Novartis to develop treatments for ...

A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com, and an archived version will be made available for 30 days ...

One of Monte Rosa Therapeutics' main differentiating factors is its proprietary QuEEN platform to design new molecular glue degraders. This process also leverages AI. They now have two important ...

Monte Rosa Therapeutics stock rises as it announces a global licensing deal with Novartis to advance MRT-6160 for immune conditions. Vandana Singh Why Westport Fuel Systems Shares Are Trading ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Upcoming Movies and TV shows Rotten Tomatoes Podcast Media News + More ...

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines ...